![[PRNewswire] Biosidus Expands Biologics Capacity for Agalsidase Beta](https://healthylife7.com/wp-content/uploads/2026/08/RPR20260827000400353_01_i_P4.jpg "[PRNewswire] Biosidus Expands Biologics Capacity for Agalsidase Beta")
— Argentine Biotech Operates New Bioreactor Plant to Boost Global Rare Disease Supply
BUENOS AIRES, Argentina Aug. 27, 2026 /PRNewswire=YONHAP/ — Biosidus, an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company’s biologics production capacity and reinforcing its ability to support potential international demand
The expansion strengthens Biosidus’ industrial platform at a time when healthcare systems are placing increasing emphasis on manufacturing reliability, continuity of treatment and diversified
Developed and manufactured in Argentina, Biosidus’ agalsidase beta, its biosimilar enzyme replacement therapy for Fabry disease, represents a significant milestone in the company’s biotechnology platform and its growing focus on treatments for rare diseases
With additional production capacity, Biosidus is strengthening its international supply capabilities and is prepared to engage with partners and health authorities evaluating sustainable and reliable
“Continuity of treatment is particularly critical for patients living with rare and chronic diseases. Expanding our productive capacity reinforces our commitment to making Biosidus’ biotechnology capabilities available to healthcare systems seeking sustainable and reliable access to high-quality biologic medicines,” said Mario Koch, Director of Rare Diseases
After launching agalsidase beta in Argentina in 2025, Biosidus is advancing the international expansion of its program and is available to evaluate extraordinary supply requirements in markets where the applicable regulatory pathways allow it
The new bioreactor capacity is part of Biosidus’ broader strategy of combining scientific capabilities, local manufacturing, industrial investment and international expansion to increase access to complex biologic therapies
Biosidus is an Argentine biotechnology company specializing in the development, manufacturing and commercialization of biosimilar medicines. With more than 40 years of experience in biotechnology and a presence in international markets, the company develops and manufactures complex biologic medicines across multiple therapeutic areas
Source: Biosidus
[※ Editor’s note = This PRESS RELEASE was provided by the news provider, and Yonhap has not edited the content in any way, nor does it reflect the editorial direction of Yonhap.](END)
Articles with issue keywords
Most Liked
Illinois declares ‘BTS Day’ ahead of Chicago concerts
(Yonhap Interview) Korea’s independence movement ‘lofty cry’ for universal values: historian
Ahn Jung-geun’s footsteps at Lushun Prison fade with removal of Korean labels
Neglected overseas Korean independence sites raise calls for better preservation
Hyundai Motor launches 2027 Palisade with high roof, new trims
Most Saved
(Yonhap Interview) Korea’s independence movement ‘lofty cry’ for universal values: historian
Hyundai Motor launches 2027 Palisade with high roof, new trims
Ahn Jung-geun’s footsteps at Lushun Prison fade with removal of Korean labels
Neglected overseas Korean independence sites raise calls for better preservation
Suspense thriller ‘Mousetrap’ reinvents Korean folktale: director
Most ViewedAll Categories
4 Jeju police officers placed on administrative leave over premature closure of missing person case
U.S. preparing for Freedom Edge joint exercise with S. Korea, Japan: U.S. Pacific Command
Several Russian military aircraft briefly enter S. Korea’s air defense zone: JCS
(3rd LD) 9 S. Koreans missing in Nepal floods; 10 others confirmed safe
Discovered body confirmed to be of woman missing in Jeju: police
Most Viewed More
Most Viewed Photos
